A provider may recommend: maintaining a current dose longer before increasing slowing titration if digestive symptoms occur remaining at a lower effective dose adjusting timing of increases pausing increases until tolerance improves Individualized adjustments help support a comfortable and sustainable approach
Retatrutide, a GIP, GLP-1 and Glucagon Receptor Agonist, for People With Type 2 Diabetes: A Randomised, Double-Blind, Placebo and Active-Controlled, Parallel-Group, Phase 2 Trial
Stepping back, its clear that BED is a serious disease and clinicians who treat it have limited tools
Following a structured meal plan and staying active will enhance the effects of the treatment
Unlimited Provider Messaging: Message your clinician anytime to discuss how youre feeling, side effects, or medication dosage